Methods of producing a beta form of a prion protein, an antibody and a prion protein aggregate, of obtaining a non-aggregated concrete form of a prion protein and a binding agent, of detecting the presence of a non-aggregate in a biological sample. fibrillar and a prion protein, antibodies and a beta form of prion protein or its aggregate in a sample, to identify a substance, to prevent and / or treat a deprived disease, to diagnose a predisposition for the presence of a prion disease and detract from a biological sample, beta form of a prion protein, antibody, hybridoma cell, agent, non-fibrillary aggregate, uses of a binding agent, an aggregate and beta form of a prion protein, kit to diagnose a disease of primary, pharmaceutical composition and vaccine composition

摘要

"METHODS OF PRODUCING A BETA FORM OF A PRIENE AAPROTEIN, AN ANTIBODY AND A PRIENE PROTEIN AGGREGATE, OF OBTAINING AN AGGREGATE BETTLE FORM A PRIENE PROTECTIN AND A LARGE AGAINSTEATING AGENT, DETECTING A DEGREE OF STEAM DEGREE. -FIBRILLATE EDE A PRIENE PROTEIN, ANTIBODIES AND A BETA FORM OF PRIENE PROTEIN OR ITS AGGREGATE IN A SAMPLE, TO IDENTIFY A AGENT, TO PREVENT AND / OR TREAT A DEPRIENCIAL DISEASE, TO DIAGNOSE A PREDICTIVE DISHESION AND DETRACT A BIOLOGICAL SAMPLE, BETA FORM OF A PRIENOUS ANTIBODY, ANTIBODY, DEHIBRIDOMA CELL, AGENT, NON-FIBRILLATE AGGREGATE, USES OF AN AGGREGATE AGENT AND A AGENT OF A AGE OF A BODY AGAIN PRIENE, PHARMACEUTICAL COMPOSITION AND VACCINE COMPOSITION ". The present invention relates to a method of producing a 225 form of a prion protein which preferably has more leaves- 225 than the helical structure- 244 and is soluble in the absence of a denaturant and / or is non -aggregated and exhibits partial resistance to proteinase K digestion. The invention also relates to the use of forma- 225 in medicine, especially to create antibodies useful in the treatment and / or diagnosis of prion diseases. The invention also relates to methods of screening compounds that are capable of inhibiting and / or reversing the conversion of the 244 form of a prion protein to a 225 form, and to uses of the compounds identified in medicine.